LIPEX Flow supports the scale-up of processes from drug discovery through to GMP at lab, pilot, intermediate and commercial-scale volumes
Evonik has launched an updated version of its drug manufacturing equipment LIPEX liposome extruders. LIPEX Flow, which is available worldwide from November 2021, offers drug developers and manufacturers a superior device for bringing liposomal drug products to market. The device is designed to meet the market need for more efficient high-pressure extruders to produce drug products requiring conventional liposomal drug delivery. These include active ingredients for applications in oncology, antifungal, antibacterial, vaccine and many other applications.
LIPEX Flow supports the scale-up of processes from drug discovery through to GMP at lab, pilot, intermediate and commercial-scale volumes.
“LIPEX Flow further reinforces our position as a fully integrated system solutions provider for the pharmaceutical industry and nicely complements our offering of products, technologies, and services for complex parenterals,” said Paul Spencer, Vice President Drug Delivery & Medical Device Solutions at Evonik Health Care. “We look forward to seeing how LIPEX Flow will provide an effective and versatile drug delivery platform for next-generation applications, spanning fields from oncology to vaccines.”
Lipid-based particles, the company says, provide a versatile drug delivery platform for APIs including small molecules, drug-lipid conjugates, proteins and peptides. Nearly 20 lipid-based drug products have already been FDA approved with many more in early and late clinical stages.
LIPEX Flow’s patent-pending design reportedly maximises the effective filter area, resulting in lower extrusion pressures. The extruder is designed to minimise process risks such as contamination, product degradation or safety when working with highly potent substances.